ADME/PK as part of a rational approach to drug discovery
- 12 September 2000
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 5 (9) , 409-414
- https://doi.org/10.1016/s1359-6446(00)01540-3
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potentialXenobiotica, 1999
- Cassette dosing: rapid in vivo assessment of pharmacokineticsPharmaceutical Science & Technology Today, 1998
- Characteristics of indirect pharmacodynamic models and applications to clinical drug responsesBritish Journal of Clinical Pharmacology, 1998
- Characterization of Pharmacodynamic Recession Slopes for Direct and Indirect Response ModelsJournal of Pharmacokinetics and Biopharmaceutics, 1998
- Managing the drug discovery/development interfaceDrug Discovery Today, 1997
- Microtiter Plate Assays for Inhibition of Human, Drug-Metabolizing Cytochromes P450Analytical Biochemistry, 1997
- Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic InteractionsClinical Pharmacokinetics, 1997
- Preclinical Drug Metabolism in the Age of High-Throughput Screening: An Industrial PerspectivePharmaceutical Research, 1997
- Design of drugs involving the concepts and theories of drug metabolism and pharmacokineticsMedicinal Research Reviews, 1996
- Pharmaceutical innovation by the seven UK‐owned pharmaceutical companies (1964‐1985).British Journal of Clinical Pharmacology, 1988